Cited by 29Reproductive tract infections researchProbiotics and Fermented FoodsAntifungal resistance and susceptibility

Comparing the Effect of Probiotic and Fluconazole on Treatment and Recurrence of Vulvovaginal Candidiasis: a Triple-Blinded Randomized Controlled Trial

Open access
Mollazadeh-Narestan, Zahra, Yavarikia, Parisa, Homayouni-Rad, Aziz, Samadi Kafil, Hossein, Mohammad-Alizadeh-Charandabi, Sakineh, Gholizadeh, Pourya, Mirghafourvand, Mojgan·2023·Probiotics and Antimicrobial Proteins

Abstract

Vaginitis is a common problem in women. Candida albicans is responsible for more than 85% of vaginal fungal infections. The aim of this study was to compare the effects of probiotic and fluconazole on the treatment and recurrence of vulvovaginal candidiasis (VVC). This triple-blinded randomized controlled trial was conducted on 80 married women, aged 18-49 years, with VVC, as confirmed by clinical and laboratory diagnosis. The participants were allocated into two groups using blocked randomization method. The fluconazole-treated group received a single dose of fluconazole (150 mg) supplemented with 30 placebo capsules of probiotic, and the probiotic-treated group got 30 probiotic capsules containing 1 × 10 9 CFU/g LA-5 with 1 fluconazole placebo capsule. The samples were taken from patients to evaluate the vaginal pH and microbiological tests before, 30-35 days, and 60-65 days after starting the treatment. The signs and symptoms were assessed before the intervention and the first and second follow-ups. Chi-square, Fisher's exact, independent t, and ANCOVA tests were then used for data analysis. There was no statistically significant difference between the two groups (p = 0.127) in the frequency of negative culture 30-35 days after starting the treatment, but the frequency of negative culture 60-65 days after starting treatment in the fluconazole group was significantly higher than that of the probiotic group (p = 0.016). The abnormal discharge and vulvovaginal erythema in the first and second follow-ups and also pruritus in the second follow-up in the fluconazole group were significantly lower than those in the probiotic group (p < 0.05). There was, however, no statistically significant difference in burning, frequent urination, dysuria, and dyspareunia between the groups (p > 0.05). Lactobacillus acidophilus supplementation had an effect similar to that of fluconazole in treating most symptoms of VVC, but it was less effective than the latter in preventing recurrence. Trial Registration: Iranian Registry of Clinical Trials (IRCT): IRCT20110826007418N5. Date of registration: 3 March 2021; URL: https://en.irct.ir/trial/50819 ; Date of first registration: 10 March 2021.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s12602-022-09997-3

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Orally administered azoles can have adverse effects including neutropenia, thrombocytopenia, hepatotoxicity, gastrointestinal disorders, and neurological disorders.

    “However, orally administered azoles can have adverse effects, including neutropenia, thrombocytopenia, hepatotoxicity, gastrointestinal disorders, and neurological disorders [67].”

    From Statins as Antifungal Agents: A Review on Drug Repurposing and Nanotechnology-Driven Delivery Strategies (2025) · cites this paper as [67]

    The Background lists neutropenia, thrombocytopenia, hepatotoxicity, gastrointestinal symptoms, and neurological symptoms as possible side effects of antifungal agents. It says antifungals can be administered orally and identifies azoles as a treatment, but does not specifically attribute every listed effect to orally administered azoles. (LLM, conf=0.82)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 6

  1. [4]Hainer BL Gibson MV Vaginitis: diagnosis and treatment Am Fam Physician 2011 83 7 807 815 21524046
  2. [17]Karimi FZ Bakhshi M Dadgar S Maleki-Saghooni N Review of anti-Trichomonas vaginalis herbs and their therapeutic effects Iran J Obstet Gynecol Infertil 2018 20 12 96 109
  3. [22]Nobahar B Javedanmehr M Herbal medicines for treatment of antifungal and bacterial vaginitis in reproductive aged women: a systematic review and meta-analysis Herald NAMSCA 2018 3 462 467
  4. [37]Ramezani_Tehrani R, Farahmand M, Abedini M, Hashemi Z (2012) Prevalance of vaginitisin iranian women--symptoms and clinical association. Islamic Azad Univ Tehran Med Brench 22(4):62–68
  5. [39]Vladareanu R, Mihu D, Mitran M et al (2018) New evidence on oral L. plantarum P17630 product in women with history of recurrent vulvovaginal candidiasis (RVVC): a randomized double-blind placebo-controlled study. Eur Rev Med Pharmacol Sci 22(1):262–267 29364495
  6. [48]Hempel S Newberry S Ruelaz A Safety of probiotics used to reduce risk and prevent or treat disease Evid Rep Technol Assess 2011 200 1 645 PMC4780970 23126627

Cited by

Sorted by citations

Authors
Mollazadeh-Narestan, Z., Yavarikia, P., Homayouni-Rad, A., Samadi Kafil, H., Mohammad-Alizadeh-Charandabi, S., Gholizadeh, P., & Mirghafourvand, M.
Affiliations
Tabriz University of Medical Sciences (IR)
Corresponding author
Yavarikia, Parisa
Venue
Probiotics and Antimicrobial Proteins
Published
2022-10-05
Volume
15
Issue
5
Pages
1436-1446
ISSN
  • 1867-1306 (ISSN-L)
  • 1867-1314
OpenAlex
W4302024630
Cited by
29
References
36
Citations by year
2026: 7 · 2025: 14 · 2024: 7 · 2023: 1
FWCI
3.44
Type
journal article
Language
en
Open access
Locations
  • Probiotics and Antimicrobial Proteins (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Immunology and Microbiology › Microbiology › Reproductive tract infections research
  • Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
Keywords
vaginal candidiasis, probiotics, fluconazole, Candida albicans, Lactobacillus acidophilus, vaginal dysbiosis, vaginal pH, vaginal discharge, pruritus, antifungal therapy, women's health, vaginal microbiota restoration, dyspareunia, dysuria
MeSH terms
Antifungal Agents, Candidiasis, Vulvovaginal, Capsules, Female, Humans, Iran, Fluconazole, Probiotics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review